Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2Phase 4 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Keratosis, Actinic 3Carcinoma, Basal Cell 1

Interventions

3-ingenyl angelate 11Photochemotherapy 7Aminolevulinic Acid 7Imiquimod 6methyl 5-aminolevulinate 5Fluorouracil 5Gels 4Diclofenac 4Cryotherapy 3BF-200 ALA 3tirbanibulin 2Therapeutics 2Solutions 2green tea extract polyphenone E 1cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion 1Ointments 1LEO 43204 1Drugs, Generic 1Deoxyribonuclease (Pyrimidine Dimer) 1Cryosurgery 1Cosmetics 15-fluorouracil, salicylic acid drug combination 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Keratosis, Actinic × BF-200 ALA × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

NCT02799069 2017-04-28

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
571 enrolled 46 charts
Dermatologic

Keratosis, Actinic

NCT02799082 2017-04-06

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Biofrontera Bioscience GmbH

Phase 3 Completed
122 enrolled 24 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡